Sector Investors News and Insights

TAGRISSO (osimertinib) showed an 84% decrease in the likelihood of disease progression or death in patients with unresectable, Stage III EGFR-mutated lung cancer compared to placebo in the LAURA Phase III trial.

Positive results from the LAURA Phase III trial showed AstraZenecas TAGRISSO (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free…

Read More: https://www.businesswire.com/news/home/20240602348345/en/

More News

© 2025 ETF Sector

Scroll to Top

Subscribe to our Newsletter

Stay updated with the latests analysis and insights fromm etfsector.com

If you haven’t received your newsletter email, check your spam/junk folder and add us to your contacts to ensure delivery.